SEPSIS AND SEPTIC SHOCK: CURRENT DEFINITIONS, DIAGNOSIS AND MANAGEMENT - A NARRATIVE REVIEW OF INTERNATIONAL GUIDELINES

Authors

  • Jamilov Diyorbek Khurshid ogli Asia International University ,Bukhara ,Uzbekistan

Keywords:

sepsis; septic shock; Sepsis-3; SOFA; Surviving Sepsis Campaign; vasopressors; fluid resuscitation; critical care.

Abstract

Sepsis and septic shock remain leading causes of in-hospital and global mortality, and international recommendations changed substantially with the 2026 Surviving Sepsis Campaign (SSC) update. This narrative review summarizes the Sepsis-3 definitions and diagnostic criteria, current concepts of sepsis immunopathology, and the SSC 2026 recommendations for adults on resuscitation, antimicrobial therapy, vasopressors and adjunctive care. Global Burden of Disease estimates attribute 48.9 million incident cases and 11.0 million sepsis-related deaths to 2017, equal to 19.7% of all deaths. Sepsis is identified by suspected infection with an acute increase of at least 2 SOFA points, and septic shock by a vasopressor requirement to maintain a mean arterial pressure (MAP) of at least 65 mm Hg with lactate > 2 mmol/L despite adequate fluid resuscitation, which carries hospital mortality above 40%. SSC 2026 recommends antimicrobial therapy within 1 hour in septic shock, at least 30 mL/kg of crystalloid in the first 3 hours (conditional), norepinephrine as the first-line vasopressor, an initial MAP target of 65 mm Hg, and NEWS, NEWS2, MEWS or SIRS rather than qSOFA as a single screening tool. Most recommendations are conditional and rest on low or very low certainty of evidence. The review is non-systematic, relies on a limited set of guideline and consensus documents, and does not replace clinical judgement or local protocols.

References

1.Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8), 801–810. https://doi.org/10.1001/jama.2016.0287

2.Rudd, K. E., Johnson, S. C., Agesa, K. M., Shackelford, K. A., Tsoi, D., Kievlan, D. R., et al. (2020). Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet, 395(10219), 200–211. https://doi.org/10.1016/S0140-6736(19)32989-7

3.Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., et al. (2026). Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Medicine, 52(5), 863–936; also published in Critical Care Medicine. https://doi.org/10.1097/CCM.0000000000007075

4.Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 101(6), 1644–1655. https://doi.org/10.1378/chest.101.6.1644

5.Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., et al. (2003). 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine, 31(4), 1250–1256. https://doi.org/10.1097/01.CCM.0000050454.01978.3B

6.Shankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., et al. (2016). Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8), 775–787. https://doi.org/10.1001/jama.2016.0289

7.Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., et al. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 47(11), 1181–1247. https://doi.org/10.1007/s00134-021-06506-y

8.Weiss, S. L., Peters, M. J., Oczkowski, S. J. W., Belley-Cote, E., Buysse, C., Choong, K. L. M., et al. (2026). Surviving Sepsis Campaign international guidelines for the management of sepsis and septic shock in children 2026. Intensive Care Medicine, 52(5), 937–983.

9.van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017). The immunopathology of sepsis and potential therapeutic targets. Nature Reviews Immunology, 17(7), 407–420. https://doi.org/10.1038/nri.2017.36

10.van der Poll, T., Shankar-Hari, M., & Wiersinga, W. J. (2021). The immunology of sepsis. Immunity, 54(11), 2450–2464. https://doi.org/10.1016/j.immuni.2021.10.012

Published

2026-11-11